Iradimed (IRMD) Net Cash Flow Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -32.51% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | -87.87% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 42.74% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -11.49% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -87.88% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -48.90% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 129.29% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -65.12% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 33.47% |
| 10 | Iradimed | 1.17 Bn | 1.11 Bn | 16.81 Mn | 32.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.83% |
| Dec 31, 2025 | -62.18% |
| Sep 30, 2025 | 0.92% |
| Jun 30, 2025 | 15.91% |
| Mar 31, 2025 | 45.18% |
| Dec 31, 2024 | -47.93% |
| Sep 30, 2024 | -0.27% |
| Jun 30, 2024 | -7.87% |
| Mar 31, 2024 | -102.67% |
| Dec 31, 2023 | 6.20% |
| Sep 30, 2023 | -23.89% |
| Jun 30, 2023 | 54.78% |
| Mar 31, 2023 | -147.45% |
| Dec 31, 2022 | -21.22% |
| Sep 30, 2022 | -17.94% |
| Jun 30, 2022 | -14.50% |
| Mar 31, 2022 | -107.80% |
| Dec 31, 2021 | -5.72% |
| Sep 30, 2021 | 10.69% |
| Jun 30, 2021 | 52.13% |
| Mar 31, 2021 | -27.04% |
| Dec 31, 2020 | 144.27% |
| Sep 30, 2020 | 9.22% |
| Jun 30, 2020 | 48.15% |
| Mar 31, 2020 | 86.52% |
| Dec 31, 2019 | 41.50% |
| Sep 30, 2019 | 16.43% |
| Jun 30, 2019 | 40.87% |
| Mar 31, 2019 | 34.43% |
| Dec 31, 2018 | 4.08% |
| Sep 30, 2018 | -8.60% |
| Jun 30, 2018 | -9.21% |
| Mar 31, 2018 | 12.67% |
| Dec 31, 2017 | 71.51% |
| Sep 30, 2017 | -51.24% |
| Jun 30, 2017 | -35.45% |
| Mar 31, 2017 | -37.07% |
| Dec 31, 2016 | 59.86% |
| Sep 30, 2016 | 226.88% |